Trial Profile
A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2011
Price :
$35
*
At a glance
- Drugs Roledumab (Primary) ; Anti-D Rh0 immunoglobulin
- Indications Haemolytic disease of newborn
- Focus Therapeutic Use
- 12 Oct 2011 New trial record